1
|
You L, Hong X, Wu H, Liang D, Li F, Zheng D, Zhang X, Liu D, Chen Q, Yan L, Ren M, Wang W. The association of FGF-21 with the risk of newly diagnosed type-2 diabetes mellitus: a cross-sectional study in Southern China. BMC Endocr Disord 2023; 23:188. [PMID: 37658393 PMCID: PMC10472657 DOI: 10.1186/s12902-023-01426-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/24/2023] [Accepted: 08/01/2023] [Indexed: 09/03/2023] Open
Abstract
BACKGROUND This study investigated the relationship between fibroblast growth factor 21 (FGF-21) and newly diagnosed type-2 diabetes mellitus (T2DM). METHODS In this cross-sectional study, FGF-21 and T2DM risk were analyzed using restricted cubic splines with univariate or multivariate logistic regression analysis. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated via logistic regression analysis. Cluster and subgroup analyses were conducted to evaluate the associations between FGF-21 and diabetes in different subpopulations. Nomograms and ROC curves were used to explore the clinical utility of FGF-21 in the diabetes assessment model. RESULTS High levels of FGF-21 were significantly associated with a high risk of T2DM after adjusting for confounding factors in both the total population and subpopulations (P for trend < 0.001). In the total population, the ORs of diabetes with increasing FGF-21 quartiles were 1.00 (reference), 1.24 (95% CI 0.56-2.80; quartile 2), 2.47 (95% CI 1.18-5.33; quartile 3), and 3.24 (95% CI 1.53-7.14; quartile 4) in Model 4 (P < 0.001), and the trend was consistent in different subpopulations. In addition, compared with the model constructed with conventional noninvasive indicators, the AUC of the model constructed by adding FGF-21 was increased from 0.668 (95% CI: 0.602-0.733) to 0.715 (95% CI: 0.654-0.777), indicating that FGF-21 could significantly improve the risk-assessment efficiency of type-2 diabetes. CONCLUSION This study demonstrated that a high level of circulating FGF-21 was positively correlated with diabetes, and levels of FGF-21 could be an important biomarker for the assessment of diabetes risk.
Collapse
Affiliation(s)
- Lili You
- Department of Endocrinology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, No.107 Yan Jiang West Road, Guangzhou, 510120, China
- Guang Dong Clinical Research Center for Metabolic Diseases, Guangzhou, People's Republic of China
| | - Xiaosi Hong
- Department of Endocrinology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, No.107 Yan Jiang West Road, Guangzhou, 510120, China
- Guang Dong Clinical Research Center for Metabolic Diseases, Guangzhou, People's Republic of China
| | - Hongshi Wu
- Department of Endocrinology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, No.107 Yan Jiang West Road, Guangzhou, 510120, China
- Guang Dong Clinical Research Center for Metabolic Diseases, Guangzhou, People's Republic of China
| | - Diefei Liang
- Department of Endocrinology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, No.107 Yan Jiang West Road, Guangzhou, 510120, China
- Guang Dong Clinical Research Center for Metabolic Diseases, Guangzhou, People's Republic of China
| | - Feng Li
- Department of Endocrinology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, No.107 Yan Jiang West Road, Guangzhou, 510120, China
- Guang Dong Clinical Research Center for Metabolic Diseases, Guangzhou, People's Republic of China
| | - Dinghao Zheng
- Department of Endocrinology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, No.107 Yan Jiang West Road, Guangzhou, 510120, China
- Guang Dong Clinical Research Center for Metabolic Diseases, Guangzhou, People's Republic of China
| | - Xiuwei Zhang
- Department of Endocrinology, Dongguan People's Hospital, Dongguan, People's Republic of China
| | - Dan Liu
- Department of Endocrinology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, No.107 Yan Jiang West Road, Guangzhou, 510120, China
- Guang Dong Clinical Research Center for Metabolic Diseases, Guangzhou, People's Republic of China
| | - Qingyu Chen
- Department of Medical Examination Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China
| | - Li Yan
- Department of Endocrinology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, No.107 Yan Jiang West Road, Guangzhou, 510120, China
- Guang Dong Clinical Research Center for Metabolic Diseases, Guangzhou, People's Republic of China
| | - Meng Ren
- Department of Endocrinology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, No.107 Yan Jiang West Road, Guangzhou, 510120, China.
- Guang Dong Clinical Research Center for Metabolic Diseases, Guangzhou, People's Republic of China.
| | - Wei Wang
- Department of Endocrinology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, No.107 Yan Jiang West Road, Guangzhou, 510120, China.
- Guang Dong Clinical Research Center for Metabolic Diseases, Guangzhou, People's Republic of China.
- Department of Endocrinology, Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.
| |
Collapse
|